EGFR and neoplasm: In clinical practice, patients with EGFR-mutated tumour and treated with first- to third-generation EGFR-TKI showed a better progression-free survival (PFS) compared to conventional chemotherapy, making EGFR-TKI in monotherapy the current standard of care for patients with advanced or metastatic EGFR-mutated NSCLC10,11.